Trial · NCT02455557
Adverse events222
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 222
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Treatment (SurVaxM, Temozolomide) | 12 | 66 | 41 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Treatment (SurVaxM, Temozolomide) | 4 | 66 | 7 |
| other | Angina pectoris | Cardiac disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Bradycardia | Cardiac disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Tachycardia | Cardiac disorders | Treatment (SurVaxM, Temozolomide) | 3 | 66 | 9 |
| other | Deafness | Ear and labyrinth disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Excessive cerumen production | Ear and labyrinth disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Hypoacusis | Ear and labyrinth disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Tinnitus | Ear and labyrinth disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Vertigo | Ear and labyrinth disorders | Treatment (SurVaxM, Temozolomide) | 4 | 66 | 4 |
| other | Cushingoid | Endocrine disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Hypothyroidism | Endocrine disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Cataract | Eye disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Eye pain | Eye disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Visual impairment | Eye disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 3 |
| other | Constipation | Gastrointestinal disorders | Treatment (SurVaxM, Temozolomide) | 18 | 66 | 20 |
| other | Diarrhoea | Gastrointestinal disorders | Treatment (SurVaxM, Temozolomide) | 5 | 66 | 8 |
| other | Dry mouth | Gastrointestinal disorders | Treatment (SurVaxM, Temozolomide) | 1 | 66 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02455557/events